172 related articles for article (PubMed ID: 23896100)
1. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.
Beer TM; Schellhammer PF; Corman JM; Glodé LM; Hall SJ; Whitmore JB; Frohlich MW; Penson DF
Urology; 2013 Aug; 82(2):410-5. PubMed ID: 23896100
[TBL] [Abstract][Full Text] [Related]
2. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.
Antonarakis ES; Kibel AS; Yu EY; Karsh LI; Elfiky A; Shore ND; Vogelzang NJ; Corman JM; Millard FE; Maher JC; Chang NN; DeVries T; Sheikh NA; Drake CG;
Clin Cancer Res; 2017 May; 23(10):2451-2459. PubMed ID: 27836866
[No Abstract] [Full Text] [Related]
3. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
Morgans AK; Chen YH; Sweeney CJ; Jarrard DF; Plimack ER; Gartrell BA; Carducci MA; Hussain M; Garcia JA; Cella D; DiPaola RS; Patrick-Miller LJ
J Clin Oncol; 2018 Apr; 36(11):1088-1095. PubMed ID: 29522362
[TBL] [Abstract][Full Text] [Related]
4. Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
Gravis G; Marino P; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Fizazi K
Eur J Cancer; 2014 Mar; 50(5):953-62. PubMed ID: 24424105
[TBL] [Abstract][Full Text] [Related]
5. Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy.
Richard PO; Fleshner NE; Bhatt JR; Hersey KM; Chahin R; Alibhai SM
BJU Int; 2015 Nov; 116(5):744-52. PubMed ID: 24684534
[TBL] [Abstract][Full Text] [Related]
6. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
Gilbert DC; Duong T; Kynaston HG; Alhasso AA; Cafferty FH; Rosen SD; Kanaga-Sundaram S; Dixit S; Laniado M; Madaan S; Collins G; Pope A; Welland A; Nankivell M; Wassersug R; Parmar MK; Langley RE; Abel PD
BJU Int; 2017 May; 119(5):667-675. PubMed ID: 27753182
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
Beer TM; Bernstein GT; Corman JM; Glode LM; Hall SJ; Poll WL; Schellhammer PF; Jones LA; Xu Y; Kylstra JW; Frohlich MW
Clin Cancer Res; 2011 Jul; 17(13):4558-67. PubMed ID: 21558406
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.
Irani J; Salomon L; Oba R; Bouchard P; Mottet N
Lancet Oncol; 2010 Feb; 11(2):147-54. PubMed ID: 19963436
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
10. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
11. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy.
Nishiyama T; Kanazawa S; Watanabe R; Terunuma M; Takahashi K
Int J Urol; 2004 Sep; 11(9):735-41. PubMed ID: 15379937
[TBL] [Abstract][Full Text] [Related]
12. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial.
Bourke L; Gilbert S; Hooper R; Steed LA; Joshi M; Catto JW; Saxton JM; Rosario DJ
Eur Urol; 2014 May; 65(5):865-72. PubMed ID: 24119318
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.
Nelson AM; Gonzalez BD; Jim HS; Cessna JM; Sutton SK; Small BJ; Fishman MN; Zachariah B; Jacobsen PB
Support Care Cancer; 2016 Oct; 24(10):4159-66. PubMed ID: 27142516
[TBL] [Abstract][Full Text] [Related]
14. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial.
Black PC; Basen-Engquist K; Wang X; Swartz RJ; Eddings T; Matin SF; Swanson D; Wood CG; Pisters LL; Babaian RJ; Troncoso P; Pettaway CA
BJU Int; 2007 Jul; 100(1):63-9. PubMed ID: 17552954
[TBL] [Abstract][Full Text] [Related]
15. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
Gomella LG
BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
[TBL] [Abstract][Full Text] [Related]
16. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.
Cormie P; Galvão DA; Spry N; Joseph D; Chee R; Taaffe DR; Chambers SK; Newton RU
BJU Int; 2015 Feb; 115(2):256-66. PubMed ID: 24467669
[TBL] [Abstract][Full Text] [Related]
17. Nutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: a study protocol.
Baguley BJ; Skinner TL; Leveritt MD; Wright OR
BMC Cancer; 2017 Jan; 17(1):1. PubMed ID: 28049525
[TBL] [Abstract][Full Text] [Related]
18. Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy.
Storey DJ; McLaren DB; Atkinson MA; Butcher I; Frew LC; Smyth JF; Sharpe M
Ann Oncol; 2012 Jun; 23(6):1542-9. PubMed ID: 22007078
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy.
Truong PT; Berthelet E; Lee JC; Petersen R; Lim JT; Gaul CA; Pai H; Blood P; Ludgate CM
Can J Urol; 2006 Jun; 13(3):3139-46. PubMed ID: 16813705
[TBL] [Abstract][Full Text] [Related]
20. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
